New assay helps determine lymphoma subtypes simply, quickly, and inexpensively

(Elsevier Health Sciences) To differentiate the two major subtypes of diffuse large B-cell lymphoma, which differ in management and outcomes, researchers describe use of the reverse transcriptase-multiplex ligation-dependent probe amplification (RT-MLPA) assay. RT-MLPA is as accurate as the current gold standard technology and offers advantages such as simplicity, flexibility, short turnaround time, low cost, and efficiency.